Abstract
Prostaglandin (PG) D2, the major cyclooxygenase metabolite generated from immunologically stimulated mast cells, is thought to contribute to the pathogenesis of allergic diseases due to its various inflammatory effects. However, the lack of PGD2 (DP) receptor antagonists has limited the study of its essential roles in the disease state. Recent discoveries of several DP receptor antagonists, the development of the mutant mouse and the discovery of a second PGD2 receptor, CRTH2 (chemoattractant receptor-homologousmolecule expressed on Th2 cells) receptor, have revealed the crucial roles of PGD2 and CRTH2 receptors in allergic disorders. This review presents biological evidence that PGD2 plays an essential role in allergy disorders and discusses the therapeutic possibilities of recently reported PGD2 antagonists.
Keywords: pgd2, crth2, bwa868c, s-5751, ramatroban, indometahcin, eosinophil
Current Pharmaceutical Design
Title: Recent Progress in Work on PGD2 Antagonists for Drugs Targeting Allergic Diseases
Volume: 10 Issue: 28
Author(s): Susumu Mitsumori
Affiliation:
Keywords: pgd2, crth2, bwa868c, s-5751, ramatroban, indometahcin, eosinophil
Abstract: Prostaglandin (PG) D2, the major cyclooxygenase metabolite generated from immunologically stimulated mast cells, is thought to contribute to the pathogenesis of allergic diseases due to its various inflammatory effects. However, the lack of PGD2 (DP) receptor antagonists has limited the study of its essential roles in the disease state. Recent discoveries of several DP receptor antagonists, the development of the mutant mouse and the discovery of a second PGD2 receptor, CRTH2 (chemoattractant receptor-homologousmolecule expressed on Th2 cells) receptor, have revealed the crucial roles of PGD2 and CRTH2 receptors in allergic disorders. This review presents biological evidence that PGD2 plays an essential role in allergy disorders and discusses the therapeutic possibilities of recently reported PGD2 antagonists.
Export Options
About this article
Cite this article as:
Mitsumori Susumu, Recent Progress in Work on PGD2 Antagonists for Drugs Targeting Allergic Diseases, Current Pharmaceutical Design 2004; 10 (28) . https://dx.doi.org/10.2174/1381612043382864
DOI https://dx.doi.org/10.2174/1381612043382864 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immune Cell-derived Vesicles: Modulators and Mediators of Inflammation
Current Pharmaceutical Design Ubiquitin-Proteasome Pathway Components as Therapeutic Targets for CNS Maladies
Current Pharmaceutical Design Viral Induced Oxidative and Inflammatory Response in Alzheimer’s Disease Pathogenesis with Identification of Potential Drug Candidates: A Systematic Review using Systems Biology Approach
Current Neuropharmacology Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease
Current Topics in Medicinal Chemistry T Cell-based Therapies for Atherosclerosis
Current Pharmaceutical Design The Promise of Dolutegravir: A Novel Second Generation Integrase Strand Transfer Inhibitor
Current Clinical Pharmacology Towards Retinoid Therapy for Alzheimers Disease
Current Alzheimer Research Development of Genetic Testing for Breast, Ovarian and Colorectal Cancer Predisposition: A Step Closer to Targeted Cancer Prevention
Current Drug Targets Does Intra-Articular Injection of Platelet-Rich Plasma Have an Effect on Cartilage Thickness in Patients with Primary Knee Osteoarthritis?
Current Rheumatology Reviews Design of Peptide Imaging Agents for Whole-body and Intraoperative Molecular Imaging
Current Medicinal Chemistry Encouraging microRNA-based Therapeutic Strategies for Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Anti-Neuroinflammatory Properties of n-3 Fatty Acids and Nano- Curcumin on Migraine Patients from Cellular to Clinical Insight: A Randomized, Double-Blind and Placebo-Controlled Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Visfatin and Rheumatoid Arthritis: Pathogenetic Implications and Clinical Utility
Current Rheumatology Reviews Conformational Flexibility in Designing Peptides for Immunology: The Molecular Dynamics Approach
Current Computer-Aided Drug Design Enriching One’s Environment in the Face of Cognitive and Functional Loss
Current Neurovascular Research Fat Digestion and its Role in Appetite Regulation and Energy Balance -The Importance of Enterostatin and Tetrahydrolipstatin
Current Medicinal Chemistry - Central Nervous System Agents Discovery and Design of Selective Cyclooxygenase-2 Inhibitors as Non-Ulcerogenic, Anti-Inflammatory Drugs with Potential Utility as Anti-Cancer Agents
Current Drug Targets Antiangiogenic Agents: Studies on Fumagillin and Curcumin Analogs
Current Pharmaceutical Design Optimized Turmeric Extract Reduces β-Amyloid and Phosphorylated Tau Protein Burden in Alzheimer’s Transgenic Mice
Current Alzheimer Research